Medivir Investor Relations Material
Medivir AB researches, develops, and sells pharmaceuticals primarily for the treatment of oncology in Sweden and internationally. It focuses on targeted therapies and vaccines. The company offers Merivo alfa, a product that has completed late stage clinical trials; MIV-711, which has completed phase I/II clinical trials; MIV-102 that has completed phase I/II clinical trial; and other projects in various phases of clinical development. Medivir AB was founded in 1987 and is headquartered in Huddinge, Sweden
Upcoming events for
Q2 20222022-08-19
Q3 20222022-11-03
Latest company events
Ticker symbol
MVIR
Country
Sweden
About the company
Investor Relations Page
Dig deeper into the Medivir fundamentals on Quartr.
- Skip straight to the Q&A session
- Receive notifications about new events
- Connect the financial calender on your phone
- Figure out why the stock is up or down
- Read the transcripts or scroll the deck
- Access earnings or press releases
